Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan.

Sonoyama, Takuhiro; Kamitani, Akari; Shibata, Risa Y; Seki, Naomi M; Omoto, Shinya; Igarashi, Kenji; Ariyasu, Mari

Sonoyama, Takuhiro; Kamitani, Akari; Shibata, Risa Y; Seki, Naomi M; Omoto, Shinya; Igarashi, Kenji; Ariyasu, Mari.

Afiliação

Sonoyama T; Shionogi & Co., Ltd., Drug Development and Regulatory Science Division, 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan.
Kamitani A; Shionogi & Co., Ltd., Drug Development and Regulatory Science Division, 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan.
Shibata RY; Shionogi & Co., Ltd., Drug Development and Regulatory Science Division, 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan.
Seki NM; Shionogi & Co., Ltd., Biopharmaceutical Research Division, 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
Omoto S; Shionogi & Co., Ltd., Biopharmaceutical Research Division, 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
Igarashi K; Shionogi & Co., Ltd., Drug Development and Regulatory Science Division, 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan.
Ariyasu M; Shionogi & Co., Ltd., Drug Development and Regulatory Science Division, 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan.

Vaccine X ; 15: 100390, 2023 Dec.

Article em En | MEDLINE | ID: mdl-37822891

Palavras-chave

Booster vaccine; COVID-19 vaccine; Cellular immunity; Clinical trial; Immunogenicity; Reactogenicity; Recombinant protein; Safety

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Vaccine X Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google